Article Text

other Versions

PDF
Progressive supranuclear palsy finally has a clinically measureable τ abnormality
  1. Glenda Halliday
  1. Correspondence to Professor Glenda Halliday, Neuroscience Research Australia, Randwick, NSW 2031, Australia; g.halliday{at}neura.edu.au

Statistics from Altmetric.com

Definitive biomarkers for both differentiating neurodegenerative diseases and monitoring their progression over time are sorely needed. This has become particularly crucial for the development of therapies targeting core disease mechanisms.2 β-Amyloid (Aβ) and associated biomarkers have revolutionised current thoughts and theories on Alzheimer's disease (AD) with the hope that significant advances in clinical therapies can now be achieved.2 The most significant change is their use to detect asymptomatic disease due to many disappointing clinical trials in definitively diagnosed symptomatic patients.3 This change in thinking has only been possible in AD due to advances in imaging and peripheral biomarker research and their application in diverse population settings.4 To date the identification of definitive biomarkers for other neurodegenerative …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • General neurology
    Dana Wagshal Sethu Sankaranarayanan Valerie Guss Tracey Hall Flora Berisha Iryna Lobach Anna Karydas Lisa Voltarelli Carole Scherling Hilary Heuer Maria Carmela Tartaglia Zachary Miller Giovanni Coppola Michael Ahlijanian Holly Soares Joel H Kramer Gil D Rabinovici Howard J Rosen Bruce L Miller Jere Meredith Adam L Boxer